


We Claim

1. A compound having the structure of Formula I,




Formula I

its pharmaceutically acceptable acid addition salts, solvates, enantiomers, diastereomers, regioisomers, N-oxides, polymorphs, prodrugs and metabolites wherein,

---- represents no bond or a single bond;

The variable n represents the integers 1 or 2;

R₁ and R₂ are selected from alkyl, cycloalkyl, or




R₃ is selected from alkyl, or cycloalkyl;

R₄ is selected from hydrogen or alkyl;

R₂ may also be hydrogen; or

R₁ and R₂ can together form a group selected from cycloalkyl or cycloalkenyl; and


R is



wherein R₅ is selected from alkyl or cycloalkyl, and wherein R₆ is selected from hydrogen, halogen or alkyl.

2. A compound according to claim 1 wherein R₁ is alkyl.
3. A compound according to claim 2 wherein R₁ is methyl.
4. A compound according to claim 1 wherein R₁ is cycloalkyl.
5. A compound according to claim 4 wherein R₁ is cyclopropyl.
6. A compound according to claim 1 wherein R₁ and R₂ together form optionally substituted cycloalkyl wherein the optional substituent(s) is/are halogen(s).
7. A compound according to claim 6 wherein R₁ and R₂ together form cyclohexyl.

8. A compound according to claim 6 wherein R₁ and R₂ together form 5,6-difluorocyclohexyl.
9. A compound according to claim 6 wherein R₁ and R₂ together form 5-chloro-6-fluorocyclohexyl.
10. A compound according to claim 1 wherein R₁ and R₂ together form optionally substituted cycloalkenyl.
11. A compound according to claim 1 wherein R₁ and R₂ together form cyclohexenyl.
12. A compound according to claim 1 wherein R₁ is $\begin{array}{c} \text{R}_3 - \text{N} - (\text{CH}_2)_m - \\ | \\ \text{R}_4 \end{array}$, wherein R₃ is alkyl, R₄ is hydrogen and m is 1.
13. A compound according to claim 12 wherein R₃ is methyl.
14. A compound according to claim 12 wherein R₃ is isopropyl.
15. A compound according to claim 1 wherein R₁ is $\begin{array}{c} \text{R}_3 - \text{N} - (\text{CH}_2)_m - \\ | \\ \text{R}_4 \end{array}$, wherein R₃ is cycloalkyl, R₄ is hydrogen and m is 1.
16. A compound according to claim 15 wherein R₃ is cyclopropyl.
17. A compound according to claim 15 wherein R₃ is cyclobutyl.
18. A compound according to claim 1 wherein R₁ is $\begin{array}{c} \text{R}_3 - \text{N} - (\text{CH}_2)_m - \\ | \\ \text{R}_4 \end{array}$, wherein R₃ is cycloalkyl, R₄ is alkyl and m is 1.
19. A compound according to claim 18 wherein R₃ is cyclopropyl, and R₄ is methyl.
20. A compound according to claim 1 wherein R₂ is hydrogen.
21. A compound according to claim 1 wherein R₂ is alkyl.
22. A compound according to claim 21 wherein R₂ is methyl.
23. A compound according to claim 1 wherein R₂ is $\begin{array}{c} \text{R}_3 - \text{N} - (\text{CH}_2)_m - \\ | \\ \text{R}_4 \end{array}$, wherein R₃ is optionally substituted alkyl wherein the optional substituent(s) is/are cycloalkyl, R₄ is hydrogen and m is 0.
24. A compound according to claim 23 wherein R₃ is methyl.
25. A compound according to claim 23 wherein R₃ is isopropyl.
26. A compound according to claim 23 wherein R₃ is cyclopropylmethyl.

27. A compound according to claim 1 wherein R_2 is $\begin{array}{c} R_3 - N - (CH_2)_m - \\ | \\ R_4 \end{array}$, wherein R_3 is optionally substituted alkyl wherein the optional substituent(s) is/are alkynyl, R_4 is hydrogen and m is 0.
28. A compound according to claim 27 wherein R_3 is prop-2-ynyl.
29. A compound according to claim 1 wherein R_2 is $\begin{array}{c} R_3 - N - (CH_2)_m - \\ | \\ R_4 \end{array}$, R_3 is cycloalkyl, R_4 is hydrogen and m is 0.
30. A compound according to claim 29 wherein R_3 is cyclopropyl.
31. A compound according to claim 29 wherein R_3 is cyclobutyl, R_4 is hydrogen.
32. A compound according to claim 1 wherein R_2 is $\begin{array}{c} R_3 - N - (CH_2)_m - \\ | \\ R_4 \end{array}$, wherein R_3 is cycloalkyl, R_4 is alkyl and m is 0.
33. A compound according to claim 32 wherein R_3 is cyclopropyl, R_4 is methyl and m is 0.
34. A compound according to claim 1 wherein R is , wherein R_5 is cycloalkyl, optionally substituted alkyl wherein the substituent(s) is/are selected from halogen(s) and cycloalkyl and R_6 is selected from hydrogen, halogen and alkyl.
35. A compound according to claim 1 wherein R is selected from 5-fluoro-2-propoxy-phenyl, 2,2,3,3-tetrafluoro-propoxy-phenyl, 2-cyclopentyloxy-5-fluoro-phenyl, 2-methoxy-5-methyl-phenyl, 5-fluoro-2-(2,2,2-trifluoro-ethoxy)-phenyl, 2,2,2-trifluoro-ethoxy-phenyl, 2-cyclopentyloxy-phenyl, 5-fluoro-2-isopropoxy-phenyl, 3-fluoro-2-isopropoxy-phenyl, 5-fluoro-2-methoxy-phenyl, 5-fluoro-2-trifluoromethoxy-phenyl, 2-methoxy-phenyl, 2-isopropoxy-phenyl, 4-fluoro-2-methoxy-phenyl, 4-fluoro-2-(2,2,2-trifluoro-ethoxy)-phenyl, 4-fluoro-2-isopropoxy-phenyl, 3-fluoro-2-methoxy-phenyl and 2-cyclopropylmethoxy-phenyl.
36. A compound, which is:
- 1-{3-[4-(5-Fluoro-2-propoxy-phenyl)-piperazin-1-yl]-propyl}-3-methyl-4-methylamino-pyrrolidine-2,5-dione (Compound No. 1)
- 2-(3-{4-[2-(2,2,3,3-Tetrafluoro-propoxy)-phenyl]-piperazin-1-yl}-propyl)-hexahydro-isindole-1,3-dione (Compound No. 3)

- 1-{3-[4-(5-Fluoro-2-propoxy-phenyl)-piperazin-1-yl]-propyl}-3-cyclopropylamino-4-methyl-pyrrolidine-2,5-dione (Compound No. 5)
- 2-{3-[4-(2-Cyclopentyloxy-5-fluoro-phenyl)-piperazin-1-yl]-propyl}-5,6-difluoro-hexahydro-isoindole-1,3-dione (Compound No. 7)
- 1-{3-[4-(2-Methoxy-5-methyl-phenyl)-piperazin-1-yl]-propyl}-3,4-dimethyl-pyrrolidine-2,5-dione (Compound No. 9)
- 1-{3-[4-(2-Methoxy-5-methyl-phenyl)-piperazin-1-yl]-propyl}-3-methyl-4-methylamino-pyrrolidine-2,5-dione (Compound No. 11)
- 1-{3-[4-(2-Methoxy-5-methyl-phenyl)-piperazin-1-yl]-propyl}-3-cyclopropylamino-4-methyl-pyrrolidine-2,5-dione (Compound No. 13)
- 1-{3-[4-(5-Fluoro-2-propoxy-phenyl)-piperazin-1-yl]-propyl}-3-cyclobutylamino-4-methyl-pyrrolidine-2,5-dione (Compound No. 15)
- 1-(3-{4-[5-Fluoro-2-(2,2,2-trifluoro-ethoxy)-phenyl]-piperazin-1-yl}-propyl)-3-cyclopropylamino-4-methyl-pyrrolidine-2,5-dione (Compound No. 17)
- 1-(3-{4-[5-Fluoro-2-(2,2,2-trifluoro-ethoxy)-phenyl]-piperazin-1-yl}-propyl)-3-methyl-4-methylamino-pyrrolidine-2,5-dione (Compound No. 19)
- 1-(3-{4-[5-Fluoro-2-(2,2,2-trifluoro-ethoxy)-phenyl]-piperazin-1-yl}-propyl)-3,4-dimethyl-pyrrolidine-2,5-dione (Compound No. 21)
- 1-(3-{4-[2-(2,2,3,3-Tetrafluoro-propoxy)-phenyl]-piperazin-1-yl}-propyl)-3,4-dimethyl-pyrrolidine-2,5-dione (Compound No. 23)
- 1-(3-{4-[2-(2,2,3,3-Tetrafluoro-propoxy)-phenyl]-piperazin-1-yl}-propyl)-3-cyclopropylamino-4-methyl-pyrrolidine-2,5-dione (Compound No. 25)
- 1-(3-{4-[2-(2,2,3,3-Tetrafluoro-propoxy)-phenyl]-piperazin-1-yl}-propyl)-3-cyclobutylamino-4-methyl-pyrrolidine-2,5-dione (Compound No. 27)
- 1-{3-[4-(2-Cyclopentyloxy-phenyl)-piperazin-1-yl]-propyl}-3-cyclobutylamino-4-methyl-pyrrolidine-2,5-dione (Compound No. 29)
- 2-{3-[4-(2-Cyclopentyloxy-5-fluoro-phenyl)-piperazin-1-yl]-propyl}-hexahydro-isoindole-1,3-dione (Compound No. 31)
- 1-{3-[4-(5-Fluoro-2-isopropoxy-phenyl)-piperazin-1-yl]-propyl}-3-methyl-4-methyl amino-pyrrolidine-2,5-dione (Compound No. 33)
- 1-{3-[4-(5-Fluoro-2-methoxy-phenyl)-piperazin-1-yl]-propyl}-3-methyl-4-methylamino-pyrrolidine-2,5-dione (Compound No. 35)

-1-{3-[4-(2-Cyclopropylmethoxy-phenyl)-piperazin-1-yl]-propyl}-3,4-dimethyl-pyrrolidine-2,5-dione (Compound No. 37)

-2-{3-[4-(5-Fluoro-2-isopropoxy-phenyl)-piperazin-1-yl]-propyl}-hexahydro-isindole-1,3-dione (Compound No. 39)

-2-{3-[4-(2-Cyclopentyloxy-5-fluoro-phenyl)-piperazin-1-yl]-propyl}-3a,4,7,7a-tetrahydro-isindole-1,3-dione (Compound No. 41)

-1-{3-[4-(2-Cyclopropylmethoxy-phenyl)-piperazin-1-yl]-propyl}-3-cyclopropylamino-4-methyl-pyrrolidine-2,5-dione (Compound No. 43)

-2-{3-[4-(5-Fluoro-2-isopropoxy-phenyl)-piperazin-1-yl]-propyl}-3a,4,7,7a-tetrahydro-isindole-1,3-dione (Compound No. 45)

-1-{3-[4-(5-Fluoro-2-isopropoxy-phenyl)-piperazin-1-yl]-propyl}-3-cyclobutylamino-4-methyl-pyrrolidine-2,5-dione (Compound No. 47)

-1-{3-[4-(3-Fluoro-2-isopropoxy-phenyl)-piperazin-1-yl]-propyl}-3-methyl-4-methylamino-pyrrolidine-2,5-dione (Compound No. 49)

-1-{3-[4-(2-Cyclopropylmethoxy-phenyl)-piperazin-1-yl]-propyl}-3-isopropylamino-4-methyl-pyrrolidine-2,5-dione (Compound No. 51)

-1-{3-[4-(2-Cyclopentyloxy-5-fluoro-phenyl)-piperazin-1-yl]-propyl}-3,4-dimethyl-pyrrolidine-2,5-dione (Compound No. 53)

-1-{3-[4-(2-Cyclopentyloxy-5-fluoro-phenyl)-piperazin-1-yl]-propyl}-3-cyclopropylamino-4-methyl-pyrrolidine-2,5-dione (Compound No. 55)

-1-{3-[4-(5-Fluoro-2-methoxy-phenyl)-piperazin-1-yl]-propyl}-3-(cyclopropylmethyl-amino)-4-methyl-pyrrolidine-2,5-dione (Compound No. 57)

-1-{3-[4-(5-Fluoro-2-isopropoxy-phenyl)-piperazin-1-yl]-propyl}-3-(cyclopropylmethyl-amino)-4-methyl-pyrrolidine-2,5-dione (Compound No. 59)

-1-{3-[4-(5-Fluoro-2-trifluoromethoxy-phenyl)-piperazin-1-yl]-propyl}-3-cyclopropylamino-4-methyl-pyrrolidine-2,5-dione (Compound No. 61)

-1-{3-[4-(2-Methoxy-phenyl)-piperazin-1-yl]-propyl}-3-(cyclopropylmethyl-amino)-4-methyl-pyrrolidine-2,5-dione (Compound No. 63)

-1-{3-[4-(2-Isopropoxy-phenyl)-piperazin-1-yl]-propyl}-3-isopropylamino-4-methyl-pyrrolidine-2,5-dione (Compound No. 65)

-1-{3-[4-(2-Isopropoxy-phenyl)-piperazin-1-yl]-propyl}-3-cyclopropylamino-4-methyl-pyrrolidine-2,5-dione (Compound No. 67)

- 1-{3-[4-(2-Methoxy-phenyl)-piperazin-1-yl]-propyl}-3-isopropylamino-4-methyl-pyrrolidine-2,5-dione (Compound No. 69)
- 1-{3-[4-(5-Fluoro-2-isopropoxy-phenyl)-piperazin-1-yl]-propyl}-3,4-dimethyl-pyrrole-2,5-dione (Compound No. 71)
- 1-{3-[4-(5-Fluoro-2-isopropoxy-phenyl)-piperazin-1-yl]-propyl}-3,4-dimethyl-pyrrolidine-2,5-dione (Compound No. 73)
- 1-{3-[4-(5-Fluoro-2-isopropoxy-phenyl)-piperazin-1-yl]-propyl}-3-cyclopropylamino-4-methyl-pyrrolidine-2,5-dione (Compound No. 75)
- 1-{3-[4-(5-Fluoro-2-isopropoxy-phenyl)-piperazin-1-yl]-propyl}-3-isopropylamino-4-methyl-pyrrolidine-2,5-dione (Compound No. 77)
- 1-{3-[4-(5-Fluoro-2-isopropoxy-phenyl)-piperazin-1-yl]-propyl}-3-(cyclopropyl-methyl-amino)-4-methyl-pyrrolidine-2,5-dione (Compound No. 79)
- 1-(3-{4-[2-(2,2,2-Trifluoro-ethoxy)-phenyl]-piperazin-1-yl}-propyl)-3,4-dimethyl-pyrrole-2,5-dione (Compound No. 81)
- 1-(3-{4-[2-(2,2,2-Trifluoro-ethoxy)-phenyl]-piperazin-1-yl}-propyl)-3,4-dimethyl-pyrrolidine-2,5-dione (Compound No. 83)
- 1-{3-[4-(2-Cyclopentyloxy-phenyl)-piperazin-1-yl]-propyl}-3,4-dimethyl-pyrrole-2,5-dione (Compound No. 85)
- 1-{3-[4-(2-Cyclopentyloxy-phenyl)-piperazin-1-yl]-propyl}-3,4-dimethyl-pyrrolidine-2,5-dione (Compound No. 87)
- 1-{3-[4-(2-Cyclopentyloxy-phenyl)-piperazin-1-yl]-propyl}-3-isopropylamino-4-methyl-pyrrolidine-2,5-dione (Compound No. 89)
- 1-{3-[4-(5-Fluoro-2-methoxy-phenyl)-piperazin-1-yl]-propyl}-3-cyclopropylamino-4-methyl-pyrrolidine-2,5-dione (Compound No. 91)
- 1-{3-[4-(2-Cyclopentyloxy-phenyl)-piperazin-1-yl]-propyl}-3-methyl-4-methylamino-pyrrolidine-2,5-dione (Compound No. 93)
- 1-{3-[4-(5-Fluoro-2-methoxy-phenyl)-piperazin-1-yl]-propyl}-3,4-dimethyl-pyrrolidine-2,5-dione (Compound No. 95)
- 1-{3-[4-(3-Fluoro-2-methoxy-phenyl)-piperazin-1-yl]-propyl}-3,4-dimethyl-pyrrole-2,5-dione (Compound No. 97)
- 1-{3-[4-(3-Fluoro-2-methoxy-phenyl)-piperazin-1-yl]-propyl}-3,4-dimethyl-pyrrolidine-2,5-dione (Compound No. 99)

- 1-{3-[4-(3-Fluoro-2-methoxy-phenyl)-piperazin-1-yl]-propyl}-3-methyl-4-methylamino-pyrrolidine-2,5-dione (Compound No. 101)
- 1-{3-[4-(3-Fluoro-2-methoxy-phenyl)-piperazin-1-yl]-propyl}-3-cyclopropylamino-4-methyl-pyrrolidine-2,5-dione (Compound No. 103)
- 1-{3-[4-(3-Fluoro-2-isopropoxy-phenyl)-piperazin-1-yl]-propyl}-3,4-dimethyl-pyrrolidine-2,5-dione (Compound No. 105)
- 1-{3-[4-(3-Fluoro-2-isopropoxy-phenyl)-piperazin-1-yl]-propyl}-3-cyclopropylamino-4-methyl-pyrrolidine-2,5-dione (Compound No. 107)
- 2-(3-{4-[2-(2,2,3,3-Tetrafluoro-propoxy)-phenyl]-piperazin-1-yl}-propyl)-3a,4,7,7a-tetrahydro-isoindole-1,3-dione (Compound No. 109)
- 2-{4-[4-[2-Isopropoxy-phenyl]-piperazin-1-yl]-butyl}-3a,4,7,7a-tetrahydro-isoindole-1,3-dione (Compound No. 111)
- 2-{3-[4-(4-Fluoro-2-methoxy-phenyl)-piperazin-1-yl]-propyl}-3a,4,7,7a-tetrahydro-isoindole-1,3-dione (Compound No. 113)
- 2-(3-{4-[4-Fluoro-2-(2,2,2-trifluoro-ethoxy)-phenyl]-piperazin-1-yl}-propyl)-3a,4,7,7a-tetrahydro-isoindole-1,3-dione (Compound No. 115)
- 2-{3-[4-(4-Fluoro-2-isopropoxy-phenyl)-piperazin-1-yl]-propyl}-3a,4,7,7a-tetrahydro-isoindole-1,3-dione (Compound No. 117)
- 2-{3-[4-(2-Isopropoxy-phenyl)-piperazin-1-yl]-propyl}-5-chloro-6-fluoro-hexahydro-isoindole-1,3-dione (Compound No. 119)
- 1-{3-[4-(5-Fluoro-2-propoxy-phenyl)-piperazin-1-yl]-propyl}-3-methyl-pyrrolidine-2,5-dione (Compound No. 121)
- 1-{3-[4-(5-Fluoro-2-propoxy-phenyl)-piperazin-1-yl]-propyl}-3-cyclopropylamino-methyl-pyrrolidine-2,5-dione (Compound No. 123)
- 1-{3-[4-(2-methoxy-5-methyl-phenyl)-piperazin-1-yl]-propyl}-3-cyclopropylamino methyl-pyrrolidine-2,5-dione (Compound No. 125)
- 1-(3-{4-[5-Fluoro-2-(2,2,2-trifluoro-ethoxy)-phenyl]-piperazin-1-yl}-propyl)-3-cyclopropylaminomethyl-pyrrolidine-2,5-dione (Compound No. 127)
- 1-(3-{4-[2-(2,2,3,3-Tetrafluoro-propoxy)-phenyl]-piperazin-1-yl}-propyl)-3-cyclopropylaminomethyl-pyrrolidine-2,5-dione (Compound No. 129)
- 1-(3-{4-[2-(2,2,3,3-tetrafluoro-propoxy)-phenyl]-piperazin-1-yl}-propyl)-3-cyclobutylamino-methyl-pyrrolidine-2,5-dione (Compound No. 131)

- 1-{3-[4-(3-Fluoro-2-methoxy-phenyl)-piperazin-1-yl]-propyl}-3-methyl-pyrrolidine-2,5-dione (Compound No. 133)
- 5-{3-[4-(5-Fluoro-2-isopropoxy-phenyl)-piperazin-1-yl]-propyl}-5-aza-spiro[2.4]heptane-4,6-dione (Compound No. 135)
- 1-{3-[4-(5-Fluoro-2-isopropoxy-phenyl)-piperazin-1-yl]-propyl}-3-methylaminomethyl-pyrrolidine-2,5-dione (Compound No. 137)
- 1-{3-[4-(2-Cyclopropylmethoxy-phenyl)-piperazin-1-yl]-propyl}-3-cyclopropylamino-methyl-pyrrolidine-2,5-dione (Compound No. 139)
- 1-{3-[4-(2-Cyclopropylmethoxy-phenyl)-piperazin-1-yl]-propyl}-3-methylamino-methyl-pyrrolidine-2,5-dione (Compound No. 141)
- 1-{3-[4-(2-Cyclopropylmethoxy-phenyl)-piperazin-1-yl]-propyl}-3-methyl-pyrrolidine-2,5-dione (Compound No. 143)
- 1-{3-[4-(2-Methoxy-phenyl)-piperazin-1-yl]-propyl}-3-methylaminomethyl-pyrrolidine-2,5-dione (Compound No. 145)
- 1-{3-[4-(2-Cyclopentylloxy-phenyl)-piperazin-1-yl]-propyl}-3-cyclopropylaminomethyl-pyrrolidine-2,5-dione (Compound No. 147)
- 1-{3-[4-(2-Cyclopentylloxy-phenyl)-piperazin-1-yl]-propyl}-3-(isopropylamino-methyl)-pyrrolidine-2,5-dione (Compound No. 149)
- 5-{3-[4-(2-Cyclopentylloxy-phenyl)-piperazin-1-yl]-propyl}-5-aza-spiro[2.4]heptane-4,6-dione (Compound No. 151)
- 1-{3-[4-(3-Fluoro-2-isopropoxy-phenyl)-piperazin-1-yl]-propyl}-3-(isopropylamino-methyl)-pyrrolidine-2,5-dione (Compound No. 153)
- 1-{3-[4-(3-Fluoro-2-isopropoxy-phenyl)-piperazin-1-yl]-propyl}-3-cyclopropylamino-methyl-pyrrolidine-2,5-dione (Compound No. 155)
- 5-{3-[4-(3-Fluoro-2-isopropoxy-phenyl)-piperazin-1-yl]-propyl}-5-aza-spiro[2.4]heptane-4,6-dione (Compound No. 157)
- 1-{3-[4-(5-Fluoro-2-isopropoxy-phenyl)-piperazin-1-yl]-propyl}-3-cyclopropylamino-methyl-pyrrolidine-2,5-dione (Compound No. 159)
- 1-{3-[4-(5-Fluoro-2-isopropoxy-phenyl)-piperazin-1-yl]-propyl}-3-(isopropylamino-methyl)-pyrrolidine-2,5-dione (Compound No. 161)
- 1-{3-[4-(2-Cyclopentylloxy-5-fluoro-phenyl)-piperazin-1-yl]-propyl}-3-[(cyclopropyl-methyl-amino)-methyl]-pyrrolidine-2,5-dione (Compound No. 163)

- 1-{3-[4-(2-Cyclopentyloxy-5-fluoro-phenyl)-piperazin-1-yl]-propyl}-3-isopropylamino-methyl-pyrrolidine-2,5-dione (Compound No. 165)
- 1-{3-[4-(2-Cyclopentyloxy-5-fluoro-phenyl)-piperazin-1-yl]-propyl}-3-cyclopropylaminomethyl-pyrrolidine-2,5-dione (Compound No. 167)
- 1-{3-[4-(2-Cyclopentyloxy-5-fluoro-phenyl)-piperazin-1-yl]-propyl}-3-methyl-pyrrolidine-2,5-dione (Compound No. 169)
- 1-{3-[4-(2-Cyclopentyloxy-5-fluoro-phenyl)-piperazin-1-yl]-propyl}-3-methyl-pyrrole-2,5-dione (Compound No. 171)
- 1-{3-[4-(2-Methoxy-phenyl)-piperazin-1-yl]-propyl}-3-methyl-4-prop-2-ynylamino-pyrrolidine-2,5-dione (Compound No. 173)
- 1-{3-[4-(4-Fluoro-2-isopropoxy-phenyl)-piperazin-1-yl]-propyl}-3-[(cyclopropyl-methyl-amino)-methyl]-pyrrolidine-2,5-dione (Compound No. 175)
- 1-{3-[4-(2-Methoxy-phenyl)-piperazin-1-yl]-propyl}-3-[(cyclopropyl-methyl-amino)-methyl]-pyrrolidine-2,5-dione (Compound No. 177)
- 1-{3-[4-(2-(2,2,2-Trifluoro-ethoxy)-phenyl)-piperazin-1-yl]-propyl}-3-[(cyclopropyl-methyl-amino)-methyl]-pyrrolidine-2,5-dione (Compound No. 179)
- 1-{3-[4-(2-Methoxy-phenyl)-piperazin-1-yl]-propyl}-3-(isopropylamino)-methyl-pyrrolidine-2,5-dione (Compound No. 181)
- 5-(3-{4-[2-(2,2,2-Trifluoro-ethoxy)-phenyl]-piperazin-1-yl}-propyl)-5-aza-spiro[2.4]heptane-4,6-dione (Compound No. 183)
- 1-{3-[4-(5-Fluoro-2-isopropoxy-phenyl)-piperazin-1-yl]-propyl}-3-methyl-pyrrole-2,5-dione (Compound No. 185)
- 1-{3-[4-(5-Fluoro-2-isopropoxy-phenyl)-piperazin-1-yl]-propyl}-3-methyl-pyrrolidine-2,5-dione (Compound No. 187)
- 1-{3-[4-(5-Fluoro-2-methoxy-phenyl)-piperazin-1-yl]-propyl}-3-methyl-pyrrole-2,5-dione (Compound No. 189)
- 1-{3-[4-(5-Fluoro-2-methoxy-phenyl)-piperazin-1-yl]-propyl}-3-methyl-pyrrolidine-2,5-dione (Compound No. 191)
- 1-{3-[4-(2-Cyclopentyloxy-phenyl)-piperazin-1-yl]-propyl}-3-methyl-pyrrolidine-2,5-dione (Compound No. 193)
- 1-{3-[4-(3-Fluoro-2-methoxy-phenyl)-piperazin-1-yl]-propyl}-3-methyl-pyrrole-2,5-dione (Compound No. 195)

-1-{3-[4-(3-Fluoro-2-isopropoxy-phenyl)-piperazin-1-yl]-propyl}-3-methyl-pyrrolidine-2,5-dione (Compound No. 197)

their pharmaceutically acceptable acid addition salts, solvates, enantiomers, diastereomers, regioisomers, N-oxides, polymorphs, prodrugs and metabolites.

37. A compound, which is:

-1-{3-[4-(5-Fluoro-2-propoxy-phenyl)-piperazin-1-yl]-propyl}-3-methyl-4-methylamino-pyrrolidine-2,5-dione hydrochloride salt (Compound No. 2)

-2-(3-{4-[2-(2,2,3,3-Tetrafluoro-propoxy)-phenyl]-piperazin-1-yl}-propyl)-hexahydro-isoindole-1,3-dione hydrochloride salt (Compound No. 4)

-1-{3-[4-(5-Fluoro-2-propoxy-phenyl)-piperazin-1-yl]-propyl}-3-cyclopropylamino-4-methyl-pyrrolidine-2,5-dione hydrochloride salt (Compound No. 6)

-2-{3-[4-(2-Cyclopentyloxy-5-fluoro-phenyl)-piperazin-1-yl]-propyl}-5,6-difluoro-hexahydro-isoindole-1,3-dione hydrochloride salt (Compound No.8)

-1-{3-[4-(2-Methoxy-5-methyl-phenyl)-piperazin-1-yl]-propyl}-3,4-dimethyl-pyrrolidine-2,5-dione hydrochloride salt (Compound No. 10)

-1-{3-[4-(2-Methoxy-5-methyl-phenyl)-piperazin-1-yl]-propyl}-3-methyl-4-methylamino-pyrrolidine-2,5-dione hydrochloride salt (Compound No. 12)

-1-{3-[4-(2-Methoxy-5-methyl-phenyl)-piperazin-1-yl]-propyl}-3-cyclopropylamino-4-methyl-pyrrolidine-2,5-dione hydrochloride salt (Compound No. 14)

-1-{3-[4-(5-Fluoro-2-propoxy-phenyl)-piperazin-1-yl]-propyl}-3-cyclobutylamino-4-methyl-pyrrolidine-2,5-dione hydrochloride salt (Compound No. 16)

-1-(3-{4-[5-Fluoro-2-(2,2,2-trifluoro-ethoxy)-phenyl]-piperazin-1-yl}-propyl)-3-cyclopropylamino-4-methyl-pyrrolidine-2,5-dione hydrochloride salt (Compound No. 18)

-1-(3-{4-[5-Fluoro-2-(2,2,2-trifluoro-ethoxy)-phenyl]-piperazin-1-yl}-propyl)-3-methyl-4-methylamino-pyrrolidine-2,5-dione hydrochloride salt (Compound No. 20)

-1-(3-{4-[5-Fluoro-2-(2,2,2-trifluoro-ethoxy)-phenyl]-piperazin-1-yl}-propyl)-3,4-dimethyl-pyrrolidine-2,5-dione hydrochloride salt (Compound No. 22)

-1-(3-{4-[2-(2,2,3,3-Tetrafluoro-propoxy)-phenyl]-piperazin-1-yl}-propyl)-3,4-dimethyl-pyrrolidine-2,5-dione hydrochloride salt (Compound No. 24)

- 1-(3-{4-[2-(2,2,3,3-Tetrafluoro-propoxy)-phenyl]-piperazin-1-yl}-propyl)-3-cyclopropylamino-4-methyl-pyrrolidine-2,5-dione hydrochloride salt (Compound No. 26)
- 1-(3-{4-[2-(2,2,3,3-Tetrafluoro-propoxy)-phenyl]-piperazin-1-yl}-propyl)-3-cyclobutylamino-4-methyl-pyrrolidine-2,5-dione hydrochloride salt (Compound No. 28)
- 1-{3-[4-(2-Cyclopentyloxy-phenyl)-piperazin-1-yl]-propyl}-3-cyclobutylamino-4-methyl-pyrrolidine-2,5-dione hydrochloride salt (Compound No. 30)
- 2-{3-[4-(2-Cyclopentyloxy-5-fluoro-phenyl)-piperazin-1-yl]-propyl}-hexahydro-isoindole-1,3-dione hydrochloride salt (Compound No. 32)
- 1-{3-[4-(5-Fluoro-2-isopropoxy-phenyl)-piperazin-1-yl]-propyl}-3-methyl-4-methyl amino-pyrrolidine-2,5-dione hydrochloride salt (Compound No. 34)
- 1-{3-[4-(5-Fluoro-2-methoxy-phenyl)-piperazin-1-yl]-propyl}-3-methyl-4-methylamino-pyrrolidine-2,5-dione hydrochloride salt (Compound No. 36)
- 1-{3-[4-(2-Cyclopropylmethoxy-phenyl)-piperazin-1-yl]-propyl}-3,4-dimethyl-pyrrolidine-2,5-dione hydrochloride salt (Compound No. 38)
- 2-{3-[4-(5-Fluoro-2-isopropoxy-phenyl)-piperazin-1-yl]-propyl}-hexahydro-isoindole-1,3-dione hydrochloride salt (Compound No. 40)
- 2-{3-[4-(2-Cyclopentyloxy-5-fluoro-phenyl)-piperazin-1-yl]-propyl}-3a,4,7,7a-tetrahydro-isoindole-1,3-dione hydrochloride salt (Compound No. 42)
- 1-{3-[4-(2-Cyclopropylmethoxy-phenyl)-piperazin-1-yl]-propyl}-3-cyclopropylamino-4-methyl-pyrrolidine-2,5-dione hydrochloride salt (Compound No. 44)
- 2-{3-[4-(5-Fluoro-2-isopropoxy-phenyl)-piperazin-1-yl]-propyl}-3a,4,7,7a-tetrahydro-isoindole-1,3-dione hydrochloride salt (Compound No. 46)
- 1-{3-[4-(5-Fluoro-2-isopropoxy-phenyl)-piperazin-1-yl]-propyl}-3-cyclobutylamino-4-methyl-pyrrolidin-2,5-dione hydrochloride salt (Compound No. 48)
- 1-{3-[4-(3-Fluoro-2-isopropoxy-phenyl)-piperazin-1-yl]-propyl}-3-methyl-4-methylamino-pyrrolidine-2,5-dione hydrochloride salt (Compound No. 50)
- 1-{3-[4-(2-Cyclopropylmethoxy-phenyl)-piperazin-1-yl]-propyl}-3-isopropylamino-4-methyl-pyrrolidine-2,5-dione hydrochloride salt (Compound No. 52)
- 1-{3-[4-(2-Cyclopentyloxy-5-fluoro-phenyl)-piperazin-1-yl]-propyl}-3,4-dimethyl-pyrrolidine-2,5-dione hydrochloride salt (Compound No. 54)

- 1-{3-[4-(2-Cyclopentyloxy-5-fluoro-phenyl)-piperazin-1-yl]-propyl}-3-cyclopropylamino-4-methyl-pyrrolidine-2,5-dione hydrochloride salt (Compound No.56)
- 1-{3-[4-(5-Fluoro-2-methoxy-phenyl)-piperazin-1-yl]-propyl}-3-(cyclopropylmethyl-amino)-4-methyl-pyrrolidine-2,5-dione hydrochloride salt (Compound No. 58)
- 1-{3-[4-(5-Fluoro-2-isopropoxy-phenyl)-piperazin-1-yl]-propyl}-3-(cyclopropylmethyl-amino)-4-methyl-pyrrolidine-2,5-dione hydrochloride salt (Compound No. 60)
- 1-{3-[4-(5-Fluoro-2-trifluoromethoxy-phenyl)-piperazin-1-yl]-propyl}-3-cyclopropylamino-4-methyl-pyrrolidine-2,5-dione hydrochloride salt (Compound No. 62)
- 1-{3-[4-(2-Methoxy-phenyl)-piperazin-1-yl]-propyl}-3-(cyclopropylmethyl-amino)-4-methyl-pyrrolidine-2,5-dione hydrochloride salt (Compound No. 64)
- 1-{3-[4-(2-Isopropoxy-phenyl)-piperazin-1-yl]-propyl}-3-isopropylamino-4-methyl-pyrrolidine-2,5-dione hydrochloride salt (Compound No. 66)
- 1-{3-[4-(2-Isopropoxy-phenyl)-piperazin-1-yl]-propyl}-3-cyclopropylamino-4-methyl-pyrrolidine-2,5-dione hydrochloride salt (Compound No. 68)
- 1-{3-[4-(2-Methoxy-phenyl)-piperazin-1-yl]-propyl}-3-isopropylamino-4-methyl-pyrrolidine-2,5-dione hydrochloride salt (Compound No. 70)
- 1-{3-[4-(5-Fluoro-2-isopropoxy-phenyl)-piperazin-1-yl]-propyl}-3,4-dimethyl-pyrrole-2,5-dione hydrochloride salt (Compound No. 72)
- 1-{3-[4-(5-Fluoro-2-isopropoxy-phenyl)-piperazin-1-yl]-propyl}-3,4-dimethyl-pyrrolidine-2,5-dione hydrochloride salt (Compound No. 74)
- 1-{3-[4-(5-Fluoro-2-isopropoxy-phenyl)-piperazin-1-yl]-propyl}-3-cyclopropylamino-4-methyl-pyrrolidine-2,5-dione hydrochloride salt (Compound No. 76)
- 1-{3-[4-(5-Fluoro-2-isopropoxy-phenyl)-piperazin-1-yl]-propyl}-3-isopropylamino-4-methyl-pyrrolidine-2,5-dione hydrochloride salt (Compound No. 78)
- 1-{3-[4-(5-Fluoro-2-isopropoxy-phenyl)-piperazin-1-yl]-propyl}-3-(cyclopropylmethyl-amino)-4-methyl-pyrrolidine-2,5-dione hydrochloride salt (Compound No. 80)
- 1-{3-[4-(2,2,2-Trifluoro-ethoxy)-phenyl]-piperazin-1-yl}-propyl}-3,4-dimethyl-pyrrole-2,5-dione hydrochloride salt (Compound No. 82)

- 1-(3-{4-[2-(2,2,2-Trifluoro-ethoxy)-phenyl]-piperazin-1-yl}-propyl)-3,4-dimethyl-pyrrolidine-2,5-dione hydrochloride salt (Compound No. 84)
- 1-{3-[4-(2-Cyclopentyloxy-phenyl)-piperazin-1-yl]-propyl}-3,4-dimethyl-pyrrole-2,5-dione hydrochloride salt (Compound No. 86)
- 1-{3-[4-(2-Cyclopentyloxy-phenyl)-piperazin-1-yl]-propyl}-3,4-dimethyl-pyrrolidine-2,5-dione hydrochloride salt (Compound No. 88)
- 1-{3-[4-(2-Cyclopentyloxy-phenyl)-piperazin-1-yl]-propyl}-3-isopropylamino-4-methyl-pyrrolidine-2,5-dione hydrochloride salt (Compound No. 90)
- 1-{3-[4-(5-Fluoro-2-methoxy-phenyl)-piperazin-1-yl]-propyl}-3-cyclopropylamino-4-methyl-pyrrolidine-2,5-dione hydrochloride salt (Compound No. 92)
- 1-{3-[4-(2-Cyclopentyloxy-phenyl)-piperazin-1-yl]-propyl}-3-methyl-4-methylamino-pyrrolidine-2,5-dione hydrochloride salt (Compound No. 94)
- 1-{3-[4-(5-Fluoro-2-methoxy-phenyl)-piperazin-1-yl]-propyl}-3,4-dimethyl-pyrrolidine-2,5-dione hydrochloride salt (Compound No. 96)
- 1-{3-[4-(3-Fluoro-2-methoxy-phenyl)-piperazin-1-yl]-propyl}-3,4-dimethyl-pyrrole-2,5-dione hydrochloride salt (Compound No. 98)
- 1-{3-[4-(3-Fluoro-2-methoxy-phenyl)-piperazin-1-yl]-propyl}-3,4-dimethyl-pyrrolidine-2,5-dione hydrochloride salt (Compound No. 100)
- 1-{3-[4-(3-Fluoro-2-methoxy-phenyl)-piperazin-1-yl]-propyl}-3-methyl-4-methylamino-pyrrolidine-2,5-dione hydrochloride salt (Compound No. 102)
- 1-{3-[4-(3-Fluoro-2-methoxy-phenyl)-piperazin-1-yl]-propyl}-3-cyclopropylamino-4-methyl-pyrrolidine-2,5-dione hydrochloride salt (Compound No. 104)
- 1-{3-[4-(3-Fluoro-2-isopropoxy-phenyl)-piperazin-1-yl]-propyl}-3,4-dimethyl-pyrrolidine-2,5-dione hydrochloride salt (Compound No. 106)
- 1-{3-[4-(3-Fluoro-2-isopropoxy-phenyl)-piperazin-1-yl]-propyl}-3-cyclopropylamino-4-methyl-pyrrolidine-2,5-dione hydrochloride salt (Compound No. 108)
- 2-(3-{4-[2-(2,2,3,3-Tetrafluoro-propoxy)-phenyl]-piperazin-1-yl}-propyl)-3a,4,7,7a-tetrahydro-isoindole-1,3-dione hydrochloride salt (Compound No. 110)
- 2-{4-[4-[2-Isopropoxy-phenyl]-piperazin-1-yl]-butyl}-3a,4,7,7a-tetrahydro-isoindole-1,3-dione hydrochloride salt (Compound No. 112)


- 2-{3-[4-(4-Fluoro-2-methoxy-phenyl)-piperazin-1-yl]-propyl}-3a,4,7,7a-tetrahydro-isoindole-1,3-dione hydrochloride salt (Compound No. 114)
- 2-(3-{4-[4-Fluoro-2-(2,2,2-trifluoro-ethoxy)-phenyl]-piperazin-1-yl}-propyl)-3a,4,7,7a-tetrahydro-isoindole-1,3-dione hydrochloride salt (Compound No. 116)
- 2-{3-[4-(4-Fluoro-2-isopropoxy-phenyl)-piperazin-1-yl]-propyl}-3a,4,7,7a-tetrahydro-isoindole-1,3-dione hydrochloride salt (Compound No. 118)
- 2-{3-[4-(2-Isopropoxy-phenyl)-piperazin-1-yl]-propyl}-5-chloro-6-fluoro-hexahydro-isoindole-1,3-dione hydrochloride salt (Compound No. 120)
- 1-{3-[4-(5-Fluoro-2-propoxy-phenyl)-piperazin-1-yl]-propyl}-3-methyl-pyrrolidine-2,5-dione hydrochloride salt (Compound No. 122)
- 1-{3-[4-(5-Fluoro-2-propoxy-phenyl)-piperazin-1-yl]-propyl}-3-cyclopropylamino-methyl-pyrrolidine-2,5-dione hydrochloride salt (Compound No. 124)
- 1-{3-[4-(2-methoxy-5-methyl-phenyl)-piperazin-1-yl]-propyl}-3-cyclopropylamino methyl-pyrrolidine-2,5-dione hydrochloride salt (Compound No. 126)
- 1-(3-{4-[5-Fluoro-2-(2,2,2-trifluoro-ethoxy)-phenyl]-piperazin-1-yl}-propyl)-3-cyclopropylaminomethyl-pyrrolidine-2,5-dione hydrochloride salt (Compound No. 128)
- 1-(3-{4-[2-(2,2,3,3-Tetrafluoro-propoxy)-phenyl]-piperazin-1-yl}-propyl)-3-cyclopropylaminomethyl-pyrrolidine-2,5-dione hydrochloride salt (Compound No. 130)
- 1-(3-{4-[2-(2,2,3,3-tetrafluoro-propoxy)-phenyl]-piperazin-1-yl}-propyl)-3-cyclobutylamino-methyl-pyrrolidine-2,5-dione hydrochloride salt (Compound No. 132)
- 1-{3-[4-(3-Fluoro-2-methoxy-phenyl)-piperazin-1-yl]-propyl}-3-methyl-pyrrolidine-2,5-dione hydrochloride salt (Compound No. 134)
- 5-{3-[4-(5-Fluoro-2-isopropoxy-phenyl)-piperazin-1-yl]-propyl}-5-aza-spiro[2.4]heptane-4,6-dione hydrochloride salt (Compound No. 136)
- 1-{3-[4-(5-Fluoro-2-isopropoxy-phenyl)-piperazin-1-yl]-propyl}-3-methylaminomethyl-pyrrolidine-2,5-dione hydrochloride salt (Compound No. 138)
- 1-{3-[4-(2-Cyclopropylmethoxy-phenyl)-piperazin-1-yl]-propyl}-3-cyclopropylamino-methyl-pyrrolidine-2,5-dione hydrochloride salt (Compound No. 140)

- 1-{3-[4-(2-Cyclopropylmethoxy-phenyl)-piperazin-1-yl]-propyl}-3-methylamino-methyl-pyrrolidine-2,5-dione hydrochloride salt (Compound No. 142)
- 1-{3-[4-(2-Cyclopropylmethoxy-phenyl)-piperazin-1-yl]-propyl}-3-methyl-pyrrolidine-2,5-dione hydrochloride salt (Compound No. 144)
- 1-{3-[4-(2-Methoxy-phenyl)-piperazin-1-yl]-propyl}-3-methylaminomethyl-pyrrolidine-2,5-dione hydrochloride salt (Compound No. 146)
- 1-{3-[4-(2-Cyclopentyloxy-phenyl)-piperazin-1-yl]-propyl}-3-cyclopropylaminomethyl-pyrrolidine-2,5-dione hydrochloride salt (Compound No. 148)
- 1-{3-[4-(2-Cyclopentyloxy-phenyl)-piperazin-1-yl]-propyl}-3-(isopropylamino-methyl)-pyrrolidine-2,5-dione hydrochloride salt (Compound No. 150)
- 5-{3-[4-(2-Cyclopentyloxy-phenyl)-piperazin-1-yl]-propyl}-5-aza-spiro[2.4]heptane- 4,6-dione hydrochloride salt (Compound No. 152)
- 1-{3-[4-(3-Fluoro-2-isopropoxy-phenyl)-piperazin-1-yl]-propyl}-3-(isopropylamino-methyl)-pyrrolidine-2,5-dione hydrochloride salt (Compound No. 154)
- 1-{3-[4-(3-Fluoro-2-isopropoxy-phenyl)-piperazin-1-yl]-propyl}-3-cyclopropylamino-methyl-pyrrolidine-2,5-dione hydrochloride salt (Compound No. 156)
- 5-{3-[4-(3-Fluoro-2-isopropoxy-phenyl)-piperazin-1-yl]-propyl}-5-aza-spiro[2.4]heptane- 4,6-dione hydrochloride salt (Compound No. 158)
- 1-{3-[4-(5-Fluoro-2-isopropoxy-phenyl)-piperazin-1-yl]-propyl}-3-cyclopropylamino-methyl-pyrrolidine-2,5-dione hydrochloride salt (Compound No. 160)
- 1-{3-[4-(5-Fluoro-2-isopropoxy-phenyl)-piperazin-1-yl]-propyl}-3-(isopropylamino-methyl)-pyrrolidine-2,5-dione hydrochloride salt (Compound No. 162)
- 1-{3-[4-(2-Cyclopentyloxy-5-fluoro-phenyl)-piperazin-1-yl]-propyl}-[(3-cyclopropyl-methyl-amino)-methyl]-pyrrolidine-2,5-dione hydrochloride salt (Compound No. 164)
- 1-{3-[4-(2-Cyclopentyloxy-5-fluoro-phenyl)-piperazin-1-yl]-propyl}-3-isopropylamino-methyl-pyrrolidine-2,5-dione hydrochloride salt (Compound No. 166)

- 1-{3-[4-(2-Cyclopentyloxy-5-fluoro-phenyl)-piperazin-1-yl]-propyl}-3-cyclopropylaminomethyl-pyrrolidine-2,5-dione hydrochloride salt (Compound No. 168)
- 1-{3-[4-(2-Cyclopentyloxy-5-fluoro-phenyl)-piperazin-1-yl]-propyl}-3-methyl-pyrrolidine-2,5-dione hydrochloride salt (Compound No. 170)
- 1-{3-[4-(2-Cyclopentyloxy-5-fluoro-phenyl)-piperazin-1-yl]-propyl}-3-methyl-pyrrole-2,5-dione hydrochloride salt (Compound No. 172)
- 1-{3-[4-(2-Methoxy-phenyl)-piperazin-1-yl]-propyl}-3-methyl-4-prop-2-ynylamino-pyrrolidine-2,5-dione hydrochloride salt (Compound No. 174)
- 1-{3-[4-(4-Fluoro-2-isopropoxy-phenyl)-piperazin-1-yl]-propyl}-3-[(cyclopropyl-methyl-amino)-methyl]-pyrrolidine-2,5-dione hydrochloride salt (Compound No. 176)
- 1-{3-[4-(2-methoxy-phenyl)-piperazin-1-yl]-propyl}-3-[(cyclopropyl-methyl-amino)-methyl]-pyrrolidine-2,5-dione hydrochloride salt (Compound No. 178)
- 1-(3-{4-(2-(2,2,2-Trifluoro-ethoxy)-phenyl)-piperazin-1-yl}-propyl)-3-[(cyclopropyl-methyl-amino)-methyl]-pyrrolidine-2,5-dione hydrochloride salt (Compound No. 180)
- 1-{3-[4-(2-Methoxy-phenyl)-piperazin-1-yl]-propyl}-3-(isopropylamino)-methyl-pyrrolidine-2,5-dione hydrochloride salt (Compound No. 182)
- 5-(3-{4-[2-(2,2,2-Trifluoro-ethoxy)-phenyl]-piperazin-1-yl}-propyl)-5-aza-spiro[2.4]heptane-4,6-dione hydrochloride salt (Compound No. 184)
- 1-{3-[4-(5-Fluoro-2-isopropoxy-phenyl)-piperazin-1-yl]-propyl}-3-methyl-pyrrole-2,5-dione hydrochloride salt (Compound No. 186)
- 1-{3-[4-(5-Fluoro-2-isopropoxy-phenyl)-piperazin-1-yl]-propyl}-3-methyl-pyrrolidine-2,5-dione hydrochloride salt (Compound No. 188)
- 1-{3-[4-(5-Fluoro-2-methoxy-phenyl)-piperazin-1-yl]-propyl}-3-methyl-pyrrole-2,5-dione hydrochloride salt (Compound No. 190)
- 1-{3-[4-(5-Fluoro-2-methoxy-phenyl)-piperazin-1-yl]-propyl}-3-methyl-pyrrolidine-2,5-dione hydrochloride salt (Compound No. 192)
- 1-{3-[4-(2-Cyclopentyloxy-phenyl)-piperazin-1-yl]-propyl}-3-methyl-pyrrolidine-2,5-dione hydrochloride salt (Compound No. 194)
- 1-{3-[4-(3-Fluoro-2-methoxy-phenyl)-piperazin-1-yl]-propyl}-3-methyl-pyrrole-2,5-dione hydrochloride salt (Compound No. 196)
- 1-{3-[4-(3-Fluoro-2-isopropoxy-phenyl)-piperazin-1-yl]-propyl}-3-methyl-pyrrolidine-2,5-dione hydrochloride salt (Compound No. 198)

38. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 optionally together with pharmaceutically acceptable carriers, excipients or diluents.
39. A method for treatment of a patient suffering from a disease or disorder mediated through α_{1a} and/ or α_{1d} adrenergic receptor, comprising administering to said patient a therapeutically effective amount of a compound of claim 1.
40. A method for treatment of a patient suffering from disease or disorder mediated through α_{1a} and/ or α_{1d} adrenergic receptor, comprising administering to said patient a therapeutically effective amount of a pharmaceutical composition according to claim 38.
41. The method according to claim 39 or 40 wherein a disease or disorder is benign prostatic hyperplasia.
42. A method for treatment of a patient suffering from lower urinary tract symptoms associated with or without benign prostatic hyperplasia, comprising administering to said patient a therapeutically effective amount of a compound of claim 1.
43. A method according to claim 42 wherein lower urinary tract symptoms are irritative symptoms.
44. A method according to claim 43 wherein irritative symptoms are selected from the group consisting of frequent urination, urgent urination, nocturia and unstable bladder contractions.
45. A method according to claim 42 wherein lower urinary tract symptoms are obstructive symptoms.
46. A method according to claim 45 wherein obstructive symptoms are selected from the group consisting of hesitancy, poor stream, prolong urination, and feelings of incomplete emptying.
47. A method according to claim 42 wherein the said patient is a male.
48. A method according to claim 42 wherein the said patient is a female.

49. A process for the preparation of a compound of Formula VI,



Formula VI

its pharmaceutically acceptable acid addition salts, solvates, enantiomers, diastereomers, regioisomers, N-oxides, polymorphs, prodrugs and metabolites wherein,

---- represents no bond or a single bond;

R_1 and R_2 are selected from alkyl, cycloalkyl, or

$R_3 - \underset{\substack{| \\ R_4}}{N} - (CH_2)_m -$, wherein m is the integer 0 or 1;


R_3 is selected from alkyl, or cycloalkyl;

R_4 is selected from hydrogen or alkyl;

R_2 may also be hydrogen; or

R_1 and R_2 can together form a group selected from cycloalkyl or cycloalkenyl; and


R is



wherein R_5 is selected from alkyl or cycloalkyl, and wherein R_6 is selected from hydrogen, halogen or alkyl,


the method comprising:

reacting a compound of Formula II with acrylonitrile, to give a compound of



Formula II


Formula III (wherein R is the same as defined earlier);



Formula III


hydrogenating the compound of Formula III to give a compound of Formula IV;

and




Formula IV

treating the compound of Formula IV with a compound of Formula V, to give compound of Formula VI (wherein R₁ and R₂ are the same as defined earlier).



Formula V

50. A process for the preparation of a compound of Formula X,



Formula X

its pharmaceutically acceptable acid addition salts, solvates, enantiomers, diastereomers, regioisomers, N-oxides, polymorphs, prodrugs and metabolites wherein,


R₁ is selected from alkyl, cycloalkyl, or

$R_3 - \underset{\substack{| \\ R_4}}{N} - (CH_2)_m -$, wherein m is the integer 0 or 1;

R₃ is selected from alkyl, or cycloalkyl;

R₄ is selected from hydrogen or alkyl; and


R is




wherein R₅ is selected from alkyl or cycloalkyl, and wherein R₆ is selected from hydrogen, halogen or alkyl,

the method comprising:

reacting a compound of Formula IV with a compound of Formula VII to give a compound of Formula VIII (wherein R and R₁ are the same as defined earlier);




Formula IV




Formula VII

and




Formula VIII

treating the compound of Formula VIII with a compound of Formula IX to give a compound of Formula X.,



51. A process for the preparation of a compound of Formula XI,



Formula XI

its pharmaceutically acceptable acid addition salts, solvates, enantiomers, diastereomers, regioisomers, N-oxides, polymorphs, prodrugs and metabolites wherein,


R₁ is selected from alkyl, cycloalkyl, or

$$\begin{array}{c} R_3 - N - (CH_2)_m - \\ | \\ R_4 \end{array}$$
, wherein m is the integer 0 or 1;

R₃ is selected from alkyl, or cycloalkyl;

R₄ is selected from hydrogen or alkyl;


R is



wherein R₅ is selected from alkyl or cycloalkyl, and wherein R₆ is selected from hydrogen, halogen or alkyl,


the method comprising:

reducing a compound of Formula VIII to give a compound of Formula XI.



Formula VIII


52. A process for the preparation of a compound of Formula XIII,



Formula XIII

its pharmaceutically acceptable acid addition salts, solvates, enantiomers, diastereomers, regioisomers, N-oxides, polymorphs, prodrugs and metabolites wherein,


R is



wherein R₅ is selected from alkyl or cycloalkyl, and wherein R₆ is selected from hydrogen, halogen or alkyl,


the method comprising:

reacting a compound of Formula IV with itaconic anhydride,



Formula IV


to give a compound of Formula XII (wherein R is the same as defined earlier); and



Formula XII

treatment of the compound of Formula XII with a methylene transfer reagent gives a compound of Formula XIII.

53. A process for the preparation of a compound of Formula XIV,




Formula XIV

its pharmaceutically acceptable acid addition salts, solvates, enantiomers, diastereomers, regioisomers, N-oxides, polymorphs, prodrugs and metabolites wherein,

R₃ is selected from alkyl, or cycloalkyl;

R₄ is selected from hydrogen or alkyl; and


R is



wherein R₅ is selected from alkyl or cycloalkyl, and wherein R₆ is selected from hydrogen, halogen or alkyl,

the method comprising:

treating a compound of Formula XII with a compound of Formula IX, to give a compound of Formula XIV.




Formula XII



Formula IX

54. A process for the preparation of a compound of Formula XVII,




Formula XVII

its pharmaceutically acceptable acid addition salts, solvates, enantiomers, diastereomers, regioisomers, N-oxides, polymorphs, prodrugs and metabolites wherein,

the variable n represents the integers 1 or 2; and


R is



wherein R₅ is selected from alkyl or cycloalkyl, and wherein R₆ is selected from hydrogen, halogen or alkyl,


the method comprising:

reacting 3 α ,4,7,7 α -tetrahydro-isoinidole-1,3-dione with a compound of Formula XV, to give a compound of Formula XVI (wherein X is a halogen and n is the same as defined earlier); and




Formula XV

treating the compound of Formula XVI with a compound of Formula II to give a compound of Formula XVII.




Formula XVI



Formula II

55. A process for the preparation of a compound of Formula XVIII,




Formula XVIII

its pharmaceutically acceptable acid addition salts, solvates, enantiomers, diastereomers, regioisomers, N-oxides, polymorphs, prodrugs and metabolites wherein,

the variable n represents the integers 1 or 2; and

R is




wherein R₅ is selected from alkyl or cycloalkyl, and wherein

R₆ is selected from hydrogen, halogen or alkyl,


the method comprising:

hydrogenation of a compound of Formula XVII to give a compound of

Formula XVIII.



56. A process for the preparation of a compound of Formula XXII,




Formula XXII

its pharmaceutically acceptable acid addition salts, solvates, enantiomers, diastereomers, regioisomers, N-oxides, polymorphs, prodrugs and metabolites wherein,

the variable n represents the integers 1 or 2; and


R is



wherein R₅ is selected from alkyl or cycloalkyl, and wherein R₆ is selected from hydrogen, halogen or alkyl,


the method comprising:

reacting a compound of Formula XVI with a peroxyacid,




Formula XVI

to give a compound of Formula XIX (wherein X is a halogen and n is the same as defined earlier);




Formula XIX

treating the compound of Formula XIX with a compound of Formula II to give a compound of Formula XX;



Formula XX


treating the compound of Formula XX with hydrochloric acid to give a compound of Formula XXI; and



Formula XXI

Treating the compound of Formula XXI with a fluorinating agent gives a compound of Formula XXII.


57. A process for the preparation of a compound of Formula XXIII,



its pharmaceutically acceptable acid addition salts, solvates, enantiomers, diastereomers, regioisomers, N-oxides, polymorphs, prodrugs and metabolites wherein,

the variable n represents the integers 1 or 2; and

R is



wherein R₅ is selected from alkyl or cycloalkyl, and wherein R₆ is selected from hydrogen, halogen or alkyl,

the method comprising:

reacting a compound of Formula XX with a fluorinating agent to give a compound of Formula XXIII.,

